Universal CAR 2.0 to overcome current limitations in CAR therapy
Chimeric antigen receptor (CAR) T cell therapy has effectively complemented the treatment of advanced relapsed and refractory hematological cancers. The remarkable achievements of CD19- and BCMA-CAR T therapies have raised high expectations within the fields of hematology and oncology. These groundb...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
19 June 2024
|
| In: |
Frontiers in immunology
Year: 2024, Volume: 15, Pages: 1-20 |
| ISSN: | 1664-3224 |
| DOI: | 10.3389/fimmu.2024.1383894 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.3389/fimmu.2024.1383894 Verlag, kostenfrei, Volltext: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1383894/full 
|
| Author Notes: | Lara Sophie Schlegel, Coralie Werbrouck, Michael Boettcher and Patrick Schlegel |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1911767453 | ||
| 003 | DE-627 | ||
| 005 | 20250716215006.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 241210s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2024.1383894 |2 doi | |
| 035 | |a (DE-627)1911767453 | ||
| 035 | |a (DE-599)KXP1911767453 | ||
| 035 | |a (OCoLC)1528014985 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schlegel, Lara Sophie |e VerfasserIn |0 (DE-588)1350632775 |0 (DE-627)1911768395 |4 aut | |
| 245 | 1 | 0 | |a Universal CAR 2.0 to overcome current limitations in CAR therapy |c Lara Sophie Schlegel, Coralie Werbrouck, Michael Boettcher and Patrick Schlegel |
| 246 | 3 | 3 | |a Universal CAR two point zero to overcome current limitations in CAR therapy |
| 264 | 1 | |c 19 June 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 20 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 10.12.2024 | ||
| 520 | |a Chimeric antigen receptor (CAR) T cell therapy has effectively complemented the treatment of advanced relapsed and refractory hematological cancers. The remarkable achievements of CD19- and BCMA-CAR T therapies have raised high expectations within the fields of hematology and oncology. These groundbreaking successes are propelling a collective aspiration to extend the reach of CAR therapies beyond B-lineage malignancies. Advanced CAR technologies have created a momentum to surmount the limitations of conventional CAR concepts. Most importantly, innovations that enable combinatorial targeting to address target antigen heterogeneity, using versatile adapter CAR concepts in conjunction with recent transformative next-generation CAR design, offer the promise to overcome both the bottleneck associated with CAR manufacturing and patient-individualized treatment regimens. In this comprehensive review, we delineate the fundamental prerequisites, navigate through pivotal challenges, and elucidate strategic approaches, all aimed at paving the way for the future establishment of multitargeted immunotherapies using universal CAR technologies. | ||
| 650 | 4 | |a Antibody therapies | |
| 650 | 4 | |a Cancer immune cell therapy | |
| 650 | 4 | |a CAR (chimeric antigen receptor) T-cell therapy | |
| 650 | 4 | |a Individualized cancer therapy | |
| 650 | 4 | |a iPSC (induced pluripotent stem cell) | |
| 700 | 1 | |a Werbrouck, Coralie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Boettcher, Michael |d 1982- |e VerfasserIn |0 (DE-588)138309566 |0 (DE-627)696492113 |0 (DE-576)306510219 |4 aut | |
| 700 | 1 | |a Schlegel, Patrick |d 1981- |e VerfasserIn |0 (DE-588)137178808 |0 (DE-627)590351923 |0 (DE-576)288608925 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d Lausanne : Frontiers Media, 2010 |g 15(2024), Artikel-ID 1383894, Seite 1-20 |h Online-Ressource |w (DE-627)657998354 |w (DE-600)2606827-8 |w (DE-576)343624834 |x 1664-3224 |7 nnas |a Universal CAR 2.0 to overcome current limitations in CAR therapy |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g elocationid:1383894 |g pages:1-20 |g extent:20 |a Universal CAR 2.0 to overcome current limitations in CAR therapy |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fimmu.2024.1383894 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1383894/full |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20241210 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 138309566 |a Boettcher, Michael |m 138309566:Boettcher, Michael |d 60000 |d 62200 |e 60000PB138309566 |e 62200PB138309566 |k 0/60000/ |k 1/60000/62200/ |p 3 | ||
| 999 | |a KXP-PPN1911767453 |e 4634271826 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"titleAlt":[{"title":"Universal CAR two point zero to overcome current limitations in CAR therapy"}],"language":["eng"],"person":[{"given":"Lara Sophie","role":"aut","display":"Schlegel, Lara Sophie","family":"Schlegel"},{"role":"aut","given":"Coralie","display":"Werbrouck, Coralie","family":"Werbrouck"},{"display":"Boettcher, Michael","family":"Boettcher","given":"Michael","role":"aut"},{"role":"aut","given":"Patrick","display":"Schlegel, Patrick","family":"Schlegel"}],"id":{"eki":["1911767453"],"doi":["10.3389/fimmu.2024.1383894"]},"physDesc":[{"noteIll":"Illustrationen","extent":"20 S."}],"name":{"displayForm":["Lara Sophie Schlegel, Coralie Werbrouck, Michael Boettcher and Patrick Schlegel"]},"relHost":[{"part":{"pages":"1-20","year":"2024","volume":"15","extent":"20","text":"15(2024), Artikel-ID 1383894, Seite 1-20"},"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Universal CAR 2.0 to overcome current limitations in CAR therapyFrontiers in immunology","pubHistory":["1.2010 -"],"origin":[{"dateIssuedKey":"2010","publisher":"Frontiers Media","dateIssuedDisp":"2010-","publisherPlace":"Lausanne"}],"note":["Gesehen am 07.11.13"],"title":[{"title_sort":"Frontiers in immunology","title":"Frontiers in immunology"}],"id":{"eki":["657998354"],"issn":["1664-3224"],"zdb":["2606827-8"]},"recId":"657998354","physDesc":[{"extent":"Online-Ressource"}]}],"recId":"1911767453","type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title_sort":"Universal CAR 2.0 to overcome current limitations in CAR therapy","title":"Universal CAR 2.0 to overcome current limitations in CAR therapy"}],"note":["Gesehen am 10.12.2024"],"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"19 June 2024"}]} | ||
| SRT | |a SCHLEGELLAUNIVERSALC1920 | ||